Showing 721 - 740 results of 804 for search '"inflammatory bowel disease"', query time: 0.07s Refine Results
  1. 721

    The current state of knowledge on the role of NKG2D ligands in multiple sclerosis and other autoimmune diseases by Aleksandra Pogoda-Wesołowska, Nina Sługocka, Agnieszka Synowiec, Klaudia Brodaczewska, Marcin Mejer-Zahorowski, Maciej Ziękiewicz, Wojciech Szypowski, Piotr Szymański, Adam Stępień

    Published 2025-01-01
    “…In this review, we aim to describe the role of NKG2D and NKG2DLs, and their interactions in the pathogenesis of MS, as well as in other autoimmune diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and celiac disease (CeD). …”
    Get full text
    Article
  2. 722

    Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis–A preclinical systematic review and meta-analysis by Jinchen Chong, Zepeng Chen, Jiaze Ma, Linhai He, Yijia Zhu, Zhihua Lu, Zhengxi Qiu, Chen Chen, Yugen Chen, Feng Jiang

    Published 2025-02-01
    “…Abstract Background Ulcerative colitis (UC) is a type of inflammatory bowel disease, and current treatments often fall short, necessitating new therapeutic options. …”
    Get full text
    Article
  3. 723

    Mathematical modeling in autoimmune diseases: from theory to clinical application by Yaroslav Ugolkov, Yaroslav Ugolkov, Yaroslav Ugolkov, Antonina Nikitich, Antonina Nikitich, Cristina Leon, Gabriel Helmlinger, Kirill Peskov, Kirill Peskov, Kirill Peskov, Kirill Peskov, Victor Sokolov, Victor Sokolov, Alina Volkova, Alina Volkova

    Published 2024-03-01
    “…Following a systematic literature review, 38 models describing the onset, progression, and/or the effect of treatment in 13 systemic and organ-specific autoimmune conditions were identified, most models developed for inflammatory bowel disease, multiple sclerosis, and lupus (5 models each). ≥70% of the models were developed as nonlinear systems of ordinary differential equations, others – as partial differential equations, integro-differential equations, Boolean networks, or probabilistic models. …”
    Get full text
    Article
  4. 724

    Detection of genetic determinants of potentially oncogenic representatives of the intestinal microbiota as biomarkers of colorectal cancer by Viktoriya N. Shumilova, Artemij E. Goncharov, Daniil V. Azarov, Stanislav I. Sitkin, Elgudzha L. Latariya, Batyrbek I. Aslanov, Mikhail A. Bobrakov, Rustem E. Topuzov

    Published 2024-11-01
    “…Materials and methods. 215 participants were included in the "case–control" study: 70 patients with newly diagnosed colorectal cancer, 70 patients with inflammatory bowel disease, 75 participants without diagnosed intestinal pathology. …”
    Get full text
    Article
  5. 725

    Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer by Li Liu, Min Yang, Wenxiao Dong, Tianyu Liu, Xueli Song, Yu Gu, Sinan Wang, Yi Liu, Zaripa Abla, Xiaoming Qiao, Wentian Liu, Kui Jiang, Bangmao Wang, Jie Zhang, Hailong Cao

    Published 2021-01-01
    “…Patients with prolonged inflammatory bowel disease (IBD) can develop into colorectal cancer (CRC), also called colitis-associated cancer (CAC). …”
    Get full text
    Article
  6. 726

    Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and i... by Sofia Ramiro, Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Lianne S Gensler, Helena Marzo-Ortega, Natasha de Peyrecave, Victoria Navarro-Compán, Tetsuya Tomita, Carmen Fleurinck, Ute Massow, Thomas Vaux

    Published 2025-01-01
    “…EAIR of serious infections was 1.4; no active tuberculosis was reported. Active inflammatory bowel disease and anterior uveitis EAIRs were 0.8 and 0.7, respectively. 202/303 (66.7%) patients completed Week 256. 42 (13.9%) patients discontinued treatment due to TEAEs.Efficacy at Week 48 was maintained for 5 years. …”
    Get full text
    Article
  7. 727

    Arthralgia and Extraintestinal Manifestations in Crohn’s Disease Elevate the Risk of IBD-Related Arthritis over Sacroiliitis by Ivan Giovannini, Nicola Cabas, Marco Marino, Annarita Tullio, Ilaria Tinazzi, Angela Variola, Carmelo Cicciò, Fabro Cinzia, Berretti Debora, Chiara Zuiani, Rossano Girometti, Luca Quartuccio, Alen Zabotti, Lorenzo Cereser

    Published 2024-12-01
    “…Abstract Introduction Inflammatory bowel disease (IBD) related arthritis is the most prevalent extraintestinal manifestation (EIM) of IBD, ranging between 10 and 39%. …”
    Get full text
    Article
  8. 728

    Clinical benefits and risks of remote patient monitoring: an overview and assessment of methodological rigour of systematic reviews for selected patient groups by Constanze Wartenberg, Helen Elden, Malte Frerichs, Lennart L Jivegård, Kajsa Magnusson, Georgios Mourtzinis, Ola Nyström, Kajsa Quitz, Helen Sjöland, Therese Svanberg, Helena Vallo Hult

    Published 2025-01-01
    “…The selected sixteen patient groups were: patients with asthma, chronic obstructive pulmonary disease, children and adolescents with complex needs, children and adolescents with cystic fibrosis, children and adolescents with periodic fever, elderly patients with multiple diseases, patients with eye diseases, heart failure, haematological disease, hypertension, inflammatory bowel disease, neurorehabilitation, Parkinson’s disease, psoriasis, sleep apnea, and specialist maternity care. …”
    Get full text
    Article
  9. 729

    29 m6A-RNA Methylation (Epitranscriptomic) Regulators Are Regulated in 41 Diseases including Atherosclerosis and Tumors Potentially via ROS Regulation – 102 Transcriptomic Dataset... by Ming Liu, Keman Xu, Fatma Saaoud, Ying Shao, Ruijing Zhang, Yifan Lu, Yu Sun, Charles Drummer, Li Li, Sheng Wu, Satya P. Kunapuli, Gerard J. Criner, Jianxin Sun, Huimin Shan, Xiaohua Jiang, Hong Wang, Xiaofeng Yang

    Published 2022-01-01
    “…We performed a database mining on 102 transcriptomic datasets for the expressions of 29 m6A-RNA methylation (epitranscriptomic) regulators (m6A-RMRs) in 41 diseases and cancers and made significant findings: (1) a few m6A-RMRs were upregulated; and most m6A-RMRs were downregulated in sepsis, acute respiratory distress syndrome, shock, and trauma; (2) half of 29 m6A-RMRs were downregulated in atherosclerosis; (3) inflammatory bowel disease and rheumatoid arthritis modulated m6A-RMRs more than lupus and psoriasis; (4) some organ failures shared eight upregulated m6A-RMRs; end-stage renal failure (ESRF) downregulated 85% of m6A-RMRs; (5) Middle-East respiratory syndrome coronavirus infections modulated m6A-RMRs the most among viral infections; (6) proinflammatory oxPAPC modulated m6A-RMRs more than DAMP stimulation including LPS and oxLDL; (7) upregulated m6A-RMRs were more than downregulated m6A-RMRs in cancer types; five types of cancers upregulated ≥10 m6A-RMRs; (8) proinflammatory M1 macrophages upregulated seven m6A-RMRs; (9) 86% of m6A-RMRs were differentially expressed in the six clusters of CD4+Foxp3+ immunosuppressive Treg, and 8 out of 12 Treg signatures regulated m6A-RMRs; (10) immune checkpoint receptors TIM3, TIGIT, PD-L2, and CTLA4 modulated m6A-RMRs, and inhibition of CD40 upregulated m6A-RMRs; (11) cytokines and interferons modulated m6A-RMRs; (12) NF-κB and JAK/STAT pathways upregulated more than downregulated m6A-RMRs whereas TP53, PTEN, and APC did the opposite; (13) methionine-homocysteine-methyl cycle enzyme Mthfd1 downregulated more than upregulated m6A-RMRs; (14) m6A writer RBM15 and one m6A eraser FTO, H3K4 methyltransferase MLL1, and DNA methyltransferase, DNMT1, regulated m6A-RMRs; and (15) 40 out of 165 ROS regulators were modulated by m6A eraser FTO and two m6A writers METTL3 and WTAP. …”
    Get full text
    Article
  10. 730

    Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints by Bastian Engel, David N. Assis, Mamatha Bhat, Jan Clusmann, Joost PH. Drenth, Alessio Gerussi, María-Carlota Londoño, Ye Htun Oo, Ida Schregel, Marcial Sebode, Richard Taubert

    Published 2025-02-01
    “…Although standard treatment with corticosteroids and thiopurines improves the life expectancy of patients with AIH, remission rates and tolerability are generally overestimated and the development of alternative first-line and salvage therapies has been disappointingly slow compared to in rheumatological diseases or inflammatory bowel disease. Other gaps include the lack of disease-specific diagnostic markers for AIH. …”
    Get full text
    Article
  11. 731

    Systematic identification of secondary bile acid production genes in global microbiome by Yuwei Yang, Wenxing Gao, Ruixin Zhu, Liwen Tao, Wanning Chen, Xinyue Zhu, Mengping Shen, Tingjun Xu, Tingting Zhao, Xiaobai Zhang, Lixin Zhu, Na Jiao

    Published 2025-01-01
    “…Furthermore, we highlighted the associations between secondary bile acids (SBAs) and gastrointestinal and hepatic disorders, including inflammatory bowel disease (IBD), colorectal cancer (CRC), and nonalcoholic fatty liver disease (NAFLD), further elucidating disease-specific alterations in secondary bile acid production genes. …”
    Get full text
    Article
  12. 732
  13. 733

    Quinazolinone Derivative MR2938 Protects DSS-Induced Barrier Dysfunction in Mice Through Regulating Gut Microbiota by Ling Lv, Mireguli Maimaitiming, Jichen Yang, Shuli Xia, Xin Li, Pingyuan Wang, Zhiqing Liu, Chang-Yun Wang

    Published 2025-01-01
    “…<b>Background/Objectives</b>: Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by colorectal immune infiltration and significant microbiota compositional changes. …”
    Get full text
    Article
  14. 734

    Assessment of Bowel Preparation Using Low-Volume Sulphate-Based Preparations in Comparison with Macrogols: A Multicenter, Randomized, Comparative Clinical Study of the 3rd Phase by Evgeny D. Fedorov, Viktor V. Veselov, Sergey V. Kashin, Ekaterina V. Tikhomirova, Alexey V. Veselov, Dmitry V. Zavyalov, Anne Kornowski, Tatyana Gorskaya, Magali Volteau, Thierry Ponchon

    Published 2019-03-01
    “…The safety profile of the investigated preparations in patients with inflammatory bowel disease (IBD) in remission did not differ from that in the general patient population.The differences in terms of secondary endpoints were not identified, including BBPS assessment for different sections of the colon, the level of polyp detection, the duration and completeness of colonoscopy, and the investigator’s satisfaction with the procedure. …”
    Get full text
    Article
  15. 735

    Ambulatory Surgery for Perianal Crohn’s Disease: Study of Feasibility by S. Sibio, A. Di Giorgio, M. Campanelli, S. Di Carlo, A. Divizia, C. Fiorani, R. Scaramuzzo, C. Arcudi, G. Del Vecchio Blanco, L. Biancone, G. Sica

    Published 2018-01-01
    “…All CD patients under regular follow-up at our inflammatory bowel disease referral center, presenting with symptomatic perianal fistulas, were offered surgical consultation. …”
    Get full text
    Article
  16. 736

    Lysosomes finely control macrophage inflammatory function via regulating the release of lysosomal Fe2+ through TRPML1 channel by Yanhong Xing, Meng-meng Wang, Feifei Zhang, Tianli Xin, Xinyan Wang, Rong Chen, Zhongheng Sui, Yawei Dong, Dongxue Xu, Xingyu Qian, Qixia Lu, Qingqing Li, Weijie Cai, Meiqin Hu, Yuqing Wang, Jun-li Cao, Derong Cui, Jiansong Qi, Wuyang Wang

    Published 2025-01-01
    “…More importantly, in vivo stimulation of TRPML1 ameliorates multiple clinical signs of Dextran sulfate sodium-induced colitis in mice, suggesting TRPML1 has potential in treating inflammatory bowel disease.…”
    Get full text
    Article
  17. 737

    Gut bacteria Prevotellaceae related lithocholic acid metabolism promotes colonic inflammation by Liping Chen, Zhenghao Ye, Junhua Li, Lijia Wang, Yu Chen, Meiping Yu, Jian Han, Jiangeng Huang, Dongyan Li, Yongling Lv, Kai Xiong, De’an Tian, Jiazhi Liao, Ursula Seidler, Fang Xiao

    Published 2025-01-01
    “…This study investigated the role of gut microbiota related bile acid metabolism in colonic inflammation in both patients with inflammatory bowel disease (IBD) and a murine model of dextran sulfate sodium (DSS)-induced colitis. …”
    Get full text
    Article
  18. 738

    Guidance for the gastrointestinal evaluation and management of iron deficiency in Sub-Saharan Africa by W M Simmonds, Y Awuku, C Barrett, M Brand, K Davidson, D Epstein, E Fredericks, S Gabriel, S Grobler, C Gounden, L Katsidzira, V J Louw, V Naidoo, C Noel, E Ogutu, N Ramonate, N Seabi, M Setshedi, J Van Zyl, G Watermeyer, C Kassianides

    Published 2024-02-01
    “…The recommendations incorporate six areas, namely: general recommendations and practice, Helicobacter pylori, coeliac disease, suspected small bowel bleeding, inflammatory bowel disease, and preoperative care. Implementation of the recommendations is aimed at various levels from individual practitioners to healthcare institutions, departments and regional, district, provincial and national platforms. …”
    Get full text
    Article
  19. 739

    FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial by Laith Alrubaiy, Rachel Cooney, Tariq Iqbal, Mohammed Nabil Quraishi, Susan Manzoor, Christopher Quince, Palak J Trivedi, Andrew D Beggs, Alexandra Vince, Chris Weston, Benjamin Mullish, Sahida Shabir, Nicola Jackson, Anna Rowe, Victoria Homer, Willem van Schaik, Peter Rimmer, Sarah Al-Shakhshir, Arzoo Patel, Derick Gyimah, Miriam Hares, Elena Efstathiou

    Published 2025-01-01
    “…Introduction Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven several pathogenic hypotheses to which the intestinal microbiome is proposed to contribute. …”
    Get full text
    Article
  20. 740

    Epithelial NSD2 maintains FMO‐mediated taurine biosynthesis to prevent intestinal barrier disruption by Yue Xu, Xiuying Xiao, Chunxiao Ma, Ziyi Wang, Wenxin Feng, Hanyu Rao, Wei Zhang, Ningyuan Liu, Rebiguli Aji, Xiangjun Meng, Wei‐Qiang Gao, Li Li

    Published 2024-12-01
    “…Abstract Background Inflammatory bowel disease (IBD) presents a significant challenge due to its intricate pathogenesis. …”
    Get full text
    Article